CHA Vaccine Research Institute (KOSDAQ:261780)
South Korea
· Delayed Price · Currency is KRW 3,985.00
+125.00 (3.24%)
At close: Apr 28, 2026
KOSDAQ:261780 Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Operating Revenue | 158.62 | 370.66 | 294.12 | 179.48 | 500 | Upgrade
|
| Other Revenue | -0 | -0 | -0 | -0 | - | Upgrade
|
| Revenue | 158.62 | 370.66 | 294.12 | 179.48 | 500 | Upgrade
|
| Revenue Growth (YoY) | -57.21% | 26.02% | 63.87% | -64.10% | 542.70% | Upgrade
|
| Cost of Revenue | 14.7 | 23.93 | 34.5 | 19 | - | Upgrade
|
| Gross Profit | 143.92 | 346.73 | 259.62 | 160.49 | 500 | Upgrade
|
| Selling, General & Admin | 1,981 | 1,874 | 2,197 | 2,357 | 3,199 | Upgrade
|
| Research & Development | 11,978 | 5,678 | 3,949 | 3,855 | 3,140 | Upgrade
|
| Amortization of Goodwill & Intangibles | 25.75 | 22.58 | 8.54 | 9.14 | 10.76 | Upgrade
|
| Operating Expenses | 14,415 | 8,043 | 6,679 | 6,630 | 6,585 | Upgrade
|
| Operating Income | -14,271 | -7,696 | -6,419 | -6,469 | -6,085 | Upgrade
|
| Interest Expense | -2,152 | -1,288 | -2,631 | -2,567 | -2,122 | Upgrade
|
| Interest & Investment Income | 950.2 | 1,384 | 2,282 | 1,017 | 179.88 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.69 | 10.02 | 2.67 | 0.02 | 0.17 | Upgrade
|
| Other Non Operating Income (Expenses) | -633.21 | -2,891 | 4,703 | 1,198 | -10,520 | Upgrade
|
| EBT Excluding Unusual Items | -16,107 | -10,481 | -2,063 | -6,821 | -18,546 | Upgrade
|
| Gain (Loss) on Sale of Investments | 263.18 | 66.77 | -40.4 | 105.84 | 125.77 | Upgrade
|
| Other Unusual Items | -200.68 | - | - | - | - | Upgrade
|
| Pretax Income | -16,044 | -10,414 | -2,103 | -6,715 | -18,420 | Upgrade
|
| Income Tax Expense | - | -275.5 | -353.77 | - | - | Upgrade
|
| Net Income | -16,044 | -10,138 | -1,749 | -6,715 | -18,420 | Upgrade
|
| Net Income to Common | -16,044 | -10,138 | -1,749 | -6,715 | -18,420 | Upgrade
|
| Shares Outstanding (Basic) | 27 | 27 | 27 | 26 | 23 | Upgrade
|
| Shares Outstanding (Diluted) | 27 | 27 | 27 | 26 | 23 | Upgrade
|
| Shares Change (YoY) | 0.20% | 0.76% | 0.69% | 13.39% | 30.03% | Upgrade
|
| EPS (Basic) | -597.00 | -378.00 | -65.72 | -254.00 | -790.00 | Upgrade
|
| EPS (Diluted) | -597.00 | -378.00 | -65.72 | -254.00 | -790.00 | Upgrade
|
| Free Cash Flow | -11,134 | -8,275 | -5,572 | -5,636 | -5,419 | Upgrade
|
| Free Cash Flow Per Share | -414.28 | -308.52 | -209.32 | -213.18 | -232.41 | Upgrade
|
| Gross Margin | 90.73% | 93.55% | 88.27% | 89.42% | 100.00% | Upgrade
|
| Operating Margin | -8997.23% | -2076.42% | -2182.53% | -3604.36% | -1216.93% | Upgrade
|
| Profit Margin | -10115.30% | -2735.23% | -594.82% | -3741.36% | -3684.01% | Upgrade
|
| Free Cash Flow Margin | -7019.41% | -2232.46% | -1894.38% | -3140.08% | -1083.83% | Upgrade
|
| EBITDA | -13,815 | -7,205 | -5,886 | -6,052 | -5,839 | Upgrade
|
| D&A For EBITDA | 455.64 | 491.22 | 533.31 | 417.36 | 245.49 | Upgrade
|
| EBIT | -14,271 | -7,696 | -6,419 | -6,469 | -6,085 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.